Therapeutic nanoparticles in clinics and under clinical evaluation

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm.8,2101–2141 (2011).▪▪ General review from a historic point of view of the different material categories in nanomedicine. Discusses the key factors involved in the design of new nanomedicines, as well as the important characterizations and material–cell interactions to take into account.
  Medline CASGoogle Scholar
• 2  Kreyling WG, Semmler-Behnke M, Chaudhry Q. A complementary definition of nanomaterial. Nano Today5,165–168 (2010).
  Google Scholar
• 3  Schütz CA, Juillerat-Jeanneret L, Soltmann C, Mueller H. Toxicity data of therapeutic nanoparticles in patent documents. World Patent Inf. doi:10.1016/j.wpi.2012.12.008 (2013) (Epub ahead of print).
  Google Scholar
• 4  Junghanns JU, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed.3,295–309 (2008).
  Medline CASGoogle Scholar
• 5  Heidel JD, Davis ME. Clinical developments in nanotechnology for cancer therapy. Pharm. Res.28,187–199 (2011).▪ Review on the potential and uniqueness of nanoparticles as cancer therapeutics. Details nanoparticle-based therapeutics in clinical oncology research and compares the data with previous drug formulations.
  Medline CASGoogle Scholar
• 6  Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov.7,771–782 (2008).
  Medline CASGoogle Scholar
• 7  Heath JR, Davis ME. Nanotechnology and cancer. Annu. Rev. Med.59,251–265 (2008).
  Medline CASGoogle Scholar
• 8  Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol.2,751–760 (2007).
  Medline CASGoogle Scholar
• 9  Service RF. Materials and biology. Nanotechnology takes aim at cancer. Science310,1132–1134 (2005).
  MedlineGoogle Scholar
• 10  Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov. Today17,160–166 (2012).
  Medline CASGoogle Scholar
• 11  DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther.87,272–277 (2010).
  Medline CASGoogle Scholar
• 12  Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin. Investig. Drugs20,1047–1056 (2011).
  Medline CASGoogle Scholar
• 13  Hu X, Miller L, Richman S et al. A novel PEGylated interferon β-1a for multiple sclerosis: safety, pharmacology, and biology. J. Clin. Pharmacol.52,798–808 (2012).
  Medline CASGoogle Scholar
• 14  Egger S, Lehmann RP, Height MJ, Loessner MJ, Schuppler M. Antimicrobial properties of a novel silver-silica nanocomposite material. Appl. Environ. Microbiol.75,2973–2976 (2009).
  Medline CASGoogle Scholar
• 15  Arrowsmith J. Trial watch: Phase II failures: 2008–2010. Nat. Rev. Drug Discov.10,328–329 (2011).▪▪ Statistical review of reasons for Phase II failure reported for new drugs or new indications between 2008 and 2010.
  Medline CASGoogle Scholar
• 16  Arrowsmith J. Trial watch: Phase III and submission failures: 2007–2010. Nat. Rev. Drug Discov.10,87 (2011).▪▪ Statistical review of the therapeutic areas involved and the reasons for Phase III and new drug submission failures between 2007 and 2010.
  Medline CASGoogle Scholar
• 17  Zhang JA, Xuan T, Parmar M et al. Development and characterization of a novel liposome-based formulation of SN-38. Int. J. Pharm.270,93–107 (2004).
  Medline CASGoogle Scholar
• 18  Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug. Chem.22,1879–1903 (2011).
  Medline CASGoogle Scholar
• 19  Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science338,903–910 (2012).▪▪ Recent and critical review on the potential advantages and drawbacks of multifunctional targeting nanoparticles.
  Medline CASGoogle Scholar
• 20  Vicent MJ, Ringsdorf H, Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv. Drug Deliv. Rev.61,1117–1120 (2009).▪ Preface of the special edition of Advanced Drug Delivery Reviews on polymer therapeutics. Historical review of polymer therapeutics and their importance in pharmaceutical research.
  Medline CASGoogle Scholar
• 21  Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev.61,1177–1188 (2009).▪ Overview of polyethylene glycol conjugates in clinical development, particularly for cancer therapy.
  Medline CASGoogle Scholar
• 22  Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu. Rev. Med.63,185–198 (2012).▪▪ Review on nanoparticle-based delivery platforms in cancer therapy. Discusses clinical data of nanotherapeutics on the market and in clinical trials for cancer therapy.
  Medline CASGoogle Scholar
• 23  Karussis D, Teitelbaum D, Sicsic C, Brenner T. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J. Neuroimmunol.220,125–130 (2010).
  Medline CASGoogle Scholar
• 24  Jung CW. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn. Reson. Imaging13,675–691 (1995).
  Medline CASGoogle Scholar
• 25  Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist13,248–260 (2008).
  Medline CASGoogle Scholar
• 26  Herzog C, Hartmann K, Künzi V et al. Eleven years of Inflexal V – a virosomal adjuvanted influenza vaccine. Vaccine27,4381–4387 (2009).
  Medline CASGoogle Scholar
• 27  Glantz MJ, LaFollette S, Jaeckle KA et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol.17,3110–3116 (1999).
  Medline CASGoogle Scholar
• 28  Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer6,688–701 (2006).
  Medline CASGoogle Scholar
• 29  Goldfine AB, Fonseca VA, Jones MR, Wang AC, Ford DM, Truitt KE. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm. Metab. Res.42,23–30 (2010).
  Medline CASGoogle Scholar
• 30  Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol.11,2319–2331 (2001).
  Medline CASGoogle Scholar
• 31  Simon JA; ESTRASORB Study Group. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause13,222–231 (2006).
  MedlineGoogle Scholar
• 32  Howell SB. Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology. Cancer J.7,219–227 (2001).
  Medline CASGoogle Scholar
• 33  Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin β: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs68,1139–1156 (2008).
  Medline CASGoogle Scholar
• 34  Mease PJ. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Rheumatology50,261–270 (2011).
  Medline CASGoogle Scholar
• 35  Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L. Safety of ferumoxytol in patients with anemia and CKD. Am. J. Kidney Dis.52,907–915 (2008).
  Medline CASGoogle Scholar
• 36  Anderson PM, Tomaras M, McConnell K. Mifamurtide in osteosarcoma – a practical review. Drugs Today46,327–337 (2010).
  Medline CASGoogle Scholar
• 37  Bovier PA. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev. Vaccines7,1141–1150 (2008).
  Medline CASGoogle Scholar
• 38  Gommans GM, Gommans E, van der Zant FM, Teule GJ, van der Schors TG, de Waard JW. ⁹⁹mTc nanocoll: a radiopharmaceutical for sentinel node localisation in breast cancer – in vitro and in vivo results. Appl. Radiat. Isot.67,1550–1558 (2009).
  Medline CASGoogle Scholar
• 39  Rodriguez MA, Pytlik R, Kozak T et al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal Phase 2 study. Cancer115,3475–3482 (2009).
  Medline CASGoogle Scholar
• 40  Shen LJ, Shen WC. Drug evaluation: ADI-PEG-20 – a PEGylated arginine deiminase for arginine-auxotrophic cancers. Curr. Opin. Mol. Ther.8,240–248 (2006).
  Medline CASGoogle Scholar
• 41  Vogel CL, Wojtukiewicz MZ, Carroll RR et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled Phase III study. J. Clin. Oncol.23,1178–1184 (2005).
  Medline CASGoogle Scholar
• 42  Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J. Drug Deliv.2012,581363 (2012).
  Medline CASGoogle Scholar
• 43  Herborn CU, Barkhausen J, Paetsch I et al. Coronary arteries: contrast-enhanced MR imaging with SH L 643A – experience in 12 volunteers. Radiology229,217–223 (2003).
  MedlineGoogle Scholar
• 44  Wood BJ, Poon RT, Locklin JK et al. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J. Vasc. Interv. Radiol.23,248–255 (2012).
  MedlineGoogle Scholar
• 45  Mathew J, Perez EA. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr. Opin. Oncol.23,594–600 (2011).
  Medline CASGoogle Scholar
• 46  Desai NP. Nab Technology: Nab Technology: A Drug Delivery Platform Utilising Endothelial’ gp60 Receptor-based Transport and Tumour-derived SPARC for Targeting. PharmaVentures Ltd, Oxford, UK 37–41 (2007–2008).
  Google Scholar
• 47  Rademaker-Lakhai JM, Terret C, Howell SB et al. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res.10,3386–3395 (2004).
  Medline CASGoogle Scholar
• 48  Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat. Rev. Drug Discov.9,537–550 (2010).
  Medline CASGoogle Scholar
• 49  Stern ST, Hall JB, Yu LL et al. Translational considerations for cancer nanomedicine. J. Control. Release146,164–174 (2010).
  Medline CASGoogle Scholar
• 50  Venkatraman SS, Ma LL, Natarajan JV, Chattopadhyay S. Polymer- and liposome-based nanoparticles in targeted drug delivery. Front. Biosci. (Schol. Ed.)2,801–814 (2010).
  MedlineGoogle Scholar
• 51  Svenson S, Wolfgang M, Hwang J, Ryan J, Eliasof S. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J. Control. Release153,49–55 (2011).
  Medline CASGoogle Scholar
• 52  Shiose Y, Ochi Y, Kuga H, Yamashita F, Hashida M. Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors. Biol. Pharm. Bull.30,2365–2370 (2007).
  Medline CASGoogle Scholar
• 53  Seymour LW, Ferry DR, Kerr DJ et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol.34,1629–1636 (2009).
  Medline CASGoogle Scholar
• 54  Naumovski L, Junutula JR. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr. Opin. Mol. Ther.12,248–257 (2010).
  Medline CASGoogle Scholar
• 55  Apostolidou E, Swords R, Alvarado Y, Giles FJ. Treatment of acute lymphoblastic leukaemia: a new era. Drugs67,2153–2171 (2007).
  Medline CASGoogle Scholar
• 56  Maier-Hauff K, Ulrich F, Nestler D et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol.103,317–324 (2011).
  MedlineGoogle Scholar
• 57  Plummer R, Wilson RH, Calvert H et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer104,593–598 (2011).
  Medline CASGoogle Scholar
• 58  Hamaguchi T, Doi T, Eguchi-Nakajima T et al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin. Cancer Res.16,5058–5066 (2010).
  Medline CASGoogle Scholar
• 59  Kato K, Chin K, Yoshikawa T et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs30,1621–1627 (2012).
  Medline CASGoogle Scholar
• 60  Duffaud F, Borner M, Chollet P. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. Eur. J. Cancer40,2748–2752 (2004).
  Medline CASGoogle Scholar
• 61  Ricart AD, Berlin JD, Papadopoulos KP et al. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors. Clin. Cancer Res.14,7947–7955 (2008).
  Medline CASGoogle Scholar
• 62  Scott LC, Yao JC, Benson AB 3rd et al. A Phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother. Pharmacol.63,363–370 (2009).
  Medline CASGoogle Scholar
• 63  Mueller C, Al-Batran S, Jaeger E et al. A Phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors. Program and Abstracts of the 44th American Society of Clinical Oncology Annual Meeting Chicago, IL, USA, 30 May–3 June 2008 (Abstract 2533).
  Google Scholar
• 64  Zhao H, Rubio B, Sapra P et al. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug. Chem.19,849–859 (2008).
  Medline CASGoogle Scholar
• 65  Nowotnik DP, Cvitkovic E. ProLindac (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv. Drug. Deliv. Rev.61,1214–1219 (2009).
  Medline CASGoogle Scholar
• 66  Wittgen BP, Kunst PW, van der Born K et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin. Cancer Res.13,2414–2421 (2007).
  Medline CASGoogle Scholar
• 67  Valle JW, Armstrong A, Newman C et al. A Phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest. New Drugs29,1029–1037 (2011).
  Medline CASGoogle Scholar
• 68  White SC, Lorigan P, Margison GP et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br. J. Cancer95,822–828 (2006).
  Medline CASGoogle Scholar
• 69  Constantinides PP, Chaubal MV, Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev.60,757–767 (2008).
  Medline CASGoogle Scholar
• 70  Aleku M, Schulz P, Keil O et al. Atu027, a liposomal siRNA formulation targeting PKN3, inhibits cancer progression. Cancer Res.68,9788–9798 (2008).
  Medline CASGoogle Scholar
• 71  Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J. Rheumatol.29,1942–1949 (2002).
  Medline CASGoogle Scholar
• 72  Sanna V, Sechi M. Nanoparticle therapeutics for prostate cancer treatment. Maturitas73,27–32 (2012).
  Medline CASGoogle Scholar
• 73  Eifler AC, Thaxton CS. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol. Biol.726,325–338 (2011).
  Medline CASGoogle Scholar
• 74  Danhauser-Riedl S, Hausmann E, Schick HD et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest. New Drugs11,187–195 (1993).
  Medline CASGoogle Scholar
• 75  Dritschilo A, Huang CH, Rudin CM et al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res.12,1251–1259 (2006).
  Medline CASGoogle Scholar
• 76  de Jonge MJ, Slingerland M, Loos WJ et al. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur. J. Cancer46,3016–3021 (2010).
  Medline CASGoogle Scholar
• 77  Noble CO, Krauze MT, Drummond DC et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res.66,2801–2806 (2006).
  Medline CASGoogle Scholar
• 78  Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs12,315–323 (2001).
  Medline CASGoogle Scholar
• 79  Bremerich J, Bilecen D, Reimer P. MR angiography with blood pool contrast agents. Eur. Radiol.17,3017–3024 (2007).
  MedlineGoogle Scholar
• 80  Walsh MD, Hanna SK, Sen JM et al. Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts. Clin. Cancer Res.18,2591–2602 (2012).
  Medline CASGoogle Scholar
• 81  Toudjarska I, Cai Z, Racie T et al. RNAi-mediated inhibition of activated protein C – A new approach for hemophilia treatment. Program and Abstracts of the 53rd American Society of Hematology Annual Meeting. San Diego, CA, USA, 10–13 December 2011 (Abstract 1204).
  Google Scholar
• 82  Akinc A, Chan-Daniels A, Sehgal A et al. Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia. Program and Abstracts of the 53rd American Society of Hematology Annual Meeting. San Diego, CA, USA, 10–13 December 2011 (Abstract 688).
  Google Scholar
• 83  Harada M, Bobe I, Saito H et al. Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. Cancer Sci.102,192–199 (2011).
  Medline CASGoogle Scholar
• 84  Nolte-Ernsting C, Adam G, Bücker A, Berges S, Bjørnerud A, Günther RW. Abdominal MR angiography performed using blood pool contrast agents: comparison of a new superparamagnetic iron oxide nanoparticle and a linear gadolinium polymer. Am. J. Roentgenol.171,107–113 (1998).
  Medline CASGoogle Scholar
• 85  McCoy M. A transatlantic polymeric solution – CASE STUDY#1: helped by a German custom synthesis firm, a U.S. biotech start-up tackles kidney ailment with a specialty polymer. Chem. Eng. News85,18–20 (2007).
  Google Scholar
• 86  Jensen SS, Andresen TL, Davidsen J et al. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol. Cancer Ther.3,1451–1458 (2004).
  Medline CASGoogle Scholar
• 87  Morrow KJ Jr, Bawa R, Wei C. Recent advances in basic and clinical nanomedicine. Med. Clin. N. Am.91,805–843 (2007).
  Medline CASGoogle Scholar
• 88  Bhol KC, Schechter PJ. Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis. Dig. Dis. Sci.52,2732–2742 (2007).
  Medline CASGoogle Scholar
• 89  Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst.19,1–72 (2002).
  Medline CASGoogle Scholar
• 90  Geisbert TW, Lee AC, Robbins M et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet375,1896–1905 (2010).
  Medline CASGoogle Scholar
• 101  European Comission. Nanomaterials. http://ec.europa.eu/environment/chemicals/nanotech/index.htm
  Google Scholar
• 102  US FDA. www.fda.gov
  Google Scholar
• 103  NIH clinical trials register. www.clinicaltrials.gov
  Google Scholar
• 104  Swiss Agency for Therapeutic Products (Swissmedic). www.swissmedic.ch
  Google Scholar
• 105  EMA. www.ema.europa.eu
  Google Scholar
• 106  EU. www.eurunion.org
  Google Scholar